AstraZeneca `Open' to M&A as Sales Forecast Raised on New Cancer Treatments: CEO

The CEO of AstraZeneca discusses the company's strong growth in the first half of the year, driven by significant sales increases in China and Japan. Despite anticipated slower growth due to price pressures, the company remains confident in its revised guidance. The focus is on innovation, particularly in cancer, respiratory, and cardiovascular diseases, with continued investment in R&D. While M&A is not a primary focus, strategic acquisitions are considered. AstraZeneca is also investing in emerging markets like South Korea and Vietnam, expecting long-term growth.

What is the significance of the partnership with Daichi Sankyo?

How does AstraZeneca plan to improve its cash flow?

What are AstraZeneca's expectations for their investments in Vietnam?